We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Otsuka Pharmaceutical

News List

Otsuka acquires Visterra for $430 M biospectrumasia
July 16, 2018
Otsuka’s research areas are in psychiatric and neurological diseases, hematological cancers, and kidney, cardiovascular, and infectious diseases.
Otsuka, X-Chem Partner for Drug Discovery contractpharma
December 28, 2017
Otsuka Pharmaceutical and X-Chem announced that they have signed a collaborative research agreement to advance the discovery process for new Otsuka drug compounds.
Otsuka collaborates with X-Chem for new drug compounds biospectrumasia
December 27, 2017
X-Chem will utilize its DNA-encoded library (DEX) screening and informatics platform to search for novel drug leads for several Otsuka discovery targets.
Otsuka Pharmaceutical to Acquire Neurovance americanpharmaceuticalreview
March 06, 2017
Otsuka Pharmaceutical Co. announced an agreement with Neurovance, Inc. under which OPC has agreed to acquire Neurovance, a privately held, venture-funded, clinical stage pharmaceutical company focused on attention-deficit hyperactivity disorder (ADH